Principal Monetary Group Inc. lessened its place in DexCom, Inc. (NASDAQ:DXCM – Free Report) by 3.0% through the 2nd quarter, in keeping with its most up-to-date submitting with the Securities and Trade Fee. The agency owned 774,582 shares of the medical system firm’s inventory after promoting 24,217 shares through the quarter. Principal Monetary Group Inc. owned roughly 0.19% of DexCom value $87,822,000 on the finish of the latest reporting interval.
A number of different hedge funds have additionally not too long ago purchased and offered shares of DXCM. Migdal Insurance coverage & Monetary Holdings Ltd. acquired a brand new stake in shares of DexCom within the second quarter valued at $25,000. DSM Capital Companions LLC acquired a brand new stake in DexCom within the 4th quarter valued at about $28,000. Crewe Advisors LLC bought a brand new place in shares of DexCom within the 1st quarter valued at about $29,000. Riverview Belief Co acquired a brand new place in shares of DexCom through the first quarter value about $32,000. Lastly, Smithfield Belief Co elevated its stake in shares of DexCom by 103.1% through the fourth quarter. Smithfield Belief Co now owns 325 shares of the medical system firm’s inventory value $40,000 after shopping for an extra 165 shares through the interval. Institutional buyers and hedge funds personal 97.75% of the corporate’s inventory.
DexCom Buying and selling Down 0.4 %
NASDAQ DXCM opened at $69.34 on Friday. The agency’s fifty day transferring common is $90.92 and its two-hundred day transferring common is $114.58. DexCom, Inc. has a one 12 months low of $62.34 and a one 12 months excessive of $142.00. The corporate has a debt-to-equity ratio of 1.00, a fast ratio of two.48 and a present ratio of two.82. The agency has a market cap of $27.58 billion, a PE ratio of 44.74, a P/E/G ratio of two.18 and a beta of 1.16.
DexCom (NASDAQ:DXCM – Get Free Report) final issued its quarterly earnings outcomes on Thursday, July twenty fifth. The medical system firm reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.04. DexCom had a return on fairness of 31.41% and a internet margin of 16.95%. The agency had income of $1 billion for the quarter, in comparison with analysts’ expectations of $1.04 billion. Throughout the identical quarter within the earlier 12 months, the agency posted $0.34 EPS. The agency’s income for the quarter was up 15.3% on a year-over-year foundation. Analysts anticipate that DexCom, Inc. will publish 1.69 earnings per share for the present 12 months.
Insider Transactions at DexCom
In associated information, EVP Sadie Stern offered 427 shares of DexCom inventory in a transaction on Monday, June tenth. The shares have been offered at a median value of $115.05, for a complete worth of $49,126.35. Following the transaction, the chief vice chairman now instantly owns 75,877 shares within the firm, valued at roughly $8,729,648.85. The transaction was disclosed in a authorized submitting with the SEC, which is accessible by means of this hyperlink. In different DexCom information, EVP Sadie Stern offered 427 shares of the corporate’s inventory in a transaction on Monday, June tenth. The shares have been offered at a median value of $115.05, for a complete transaction of $49,126.35. Following the completion of the transaction, the chief vice chairman now owns 75,877 shares within the firm, valued at roughly $8,729,648.85. The sale was disclosed in a authorized submitting with the SEC, which might be accessed by means of this hyperlink. Additionally, CFO Jereme M. Sylvain offered 745 shares of DexCom inventory in a transaction dated Monday, June tenth. The shares have been offered at a median value of $115.05, for a complete transaction of $85,712.25. Following the completion of the sale, the chief monetary officer now instantly owns 84,948 shares within the firm, valued at roughly $9,773,267.40. The disclosure for this sale might be discovered right here. Insiders offered 3,483 shares of firm inventory value $369,052 during the last 90 days. 0.30% of the inventory is presently owned by insiders.
Analyst Upgrades and Downgrades
Quite a few analysis analysts not too long ago issued reviews on DXCM shares. Oppenheimer decreased their value goal on shares of DexCom from $150.00 to $115.00 and set an “outperform” ranking for the corporate in a analysis notice on Friday, July twenty sixth. Robert W. Baird elevated their goal value on DexCom from $80.00 to $82.00 and gave the corporate a “impartial” ranking in a report on Monday, August fifth. BTIG Analysis decreased their value goal on DexCom from $156.00 to $120.00 and set a “purchase” ranking for the corporate in a report on Friday, July twenty sixth. Piper Sandler reaffirmed an “obese” ranking and set a $90.00 value goal on shares of DexCom in a analysis report on Monday, August twenty sixth. Lastly, Royal Financial institution of Canada lower their goal value on DexCom from $165.00 to $145.00 and set an “outperform” ranking on the inventory in a analysis report on Friday, July twenty sixth. Seven funding analysts have rated the inventory with a maintain ranking, eleven have assigned a purchase ranking and one has given a robust purchase ranking to the corporate. Based on MarketBeat, the inventory presently has a consensus ranking of “Reasonable Purchase” and a median value goal of $112.25.
Get Our Newest Inventory Report on DexCom
DexCom Profile
DexCom, Inc, a medical system firm, focuses on the design, improvement, and commercialization of steady glucose monitoring (CGM) methods in the USA and internationally. The corporate supplies its methods to be used by folks with diabetes, in addition to to be used by healthcare suppliers. Its merchandise embrace Dexcom G6 and Dexcom G7, built-in CGM methods for diabetes administration; Dexcom Share, a distant monitoring system; Dexcom Actual-Time API, which permits licensed third-party software program builders to combine real-time CGM information into their digital well being apps and units; and Dexcom ONE, that’s designed to switch finger stick blood glucose testing for diabetes remedy choices.
Featured Articles
Obtain Information & Rankings for DexCom Day by day – Enter your electronic mail deal with beneath to obtain a concise each day abstract of the most recent information and analysts’ scores for DexCom and associated corporations with MarketBeat.com’s FREE each day electronic mail e-newsletter.
